Cargando…

Establishment and Validation of an Individualized Cell Cycle Process-Related Gene Signature to Predict Cancer-Specific Survival in Patients with Bladder Cancer

More accurate models are essential to identify high-risk bladder cancer (BCa) patients who will benefit from adjuvant therapies and thus helpful to facilitate personalized management of BCa. Among various cancer-related hallmarks and pathways, cell cycle process (CCP) was identified as a dominant ri...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Run, Bao, Xuanwen, Rogowski, Paul, Schäfer, Christian, Schmidt-Hegemann, Nina-Sophie, Unger, Kristian, Lu, Shun, Sun, Jing, Buchner, Alexander, Stief, Christian, Belka, Claus, Li, Minglun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281226/
https://www.ncbi.nlm.nih.gov/pubmed/32370292
http://dx.doi.org/10.3390/cancers12051146
_version_ 1783543873466793984
author Shi, Run
Bao, Xuanwen
Rogowski, Paul
Schäfer, Christian
Schmidt-Hegemann, Nina-Sophie
Unger, Kristian
Lu, Shun
Sun, Jing
Buchner, Alexander
Stief, Christian
Belka, Claus
Li, Minglun
author_facet Shi, Run
Bao, Xuanwen
Rogowski, Paul
Schäfer, Christian
Schmidt-Hegemann, Nina-Sophie
Unger, Kristian
Lu, Shun
Sun, Jing
Buchner, Alexander
Stief, Christian
Belka, Claus
Li, Minglun
author_sort Shi, Run
collection PubMed
description More accurate models are essential to identify high-risk bladder cancer (BCa) patients who will benefit from adjuvant therapies and thus helpful to facilitate personalized management of BCa. Among various cancer-related hallmarks and pathways, cell cycle process (CCP) was identified as a dominant risk factor for cancer-specific survival (CSS) in BCa. Using a series of bioinformatic and statistical approaches, a CCP-related gene signature was established, and the prognostic value was validated in other independent BCa cohorts. In addition, the risk score derived from the gene signature serves as a promising marker for therapeutic resistance. In combination with clinicopathological features, a nomogram was constructed to provide more accurate prediction for CSS, and a decision tree was built to identify high-risk subgroup of muscle invasive BCa patients. Overall, the gene signature could be a useful tool to predict CSS and help to identify high-risk subgroup of BCa patients, which may benefit from intensified adjuvant therapy.
format Online
Article
Text
id pubmed-7281226
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72812262020-06-15 Establishment and Validation of an Individualized Cell Cycle Process-Related Gene Signature to Predict Cancer-Specific Survival in Patients with Bladder Cancer Shi, Run Bao, Xuanwen Rogowski, Paul Schäfer, Christian Schmidt-Hegemann, Nina-Sophie Unger, Kristian Lu, Shun Sun, Jing Buchner, Alexander Stief, Christian Belka, Claus Li, Minglun Cancers (Basel) Article More accurate models are essential to identify high-risk bladder cancer (BCa) patients who will benefit from adjuvant therapies and thus helpful to facilitate personalized management of BCa. Among various cancer-related hallmarks and pathways, cell cycle process (CCP) was identified as a dominant risk factor for cancer-specific survival (CSS) in BCa. Using a series of bioinformatic and statistical approaches, a CCP-related gene signature was established, and the prognostic value was validated in other independent BCa cohorts. In addition, the risk score derived from the gene signature serves as a promising marker for therapeutic resistance. In combination with clinicopathological features, a nomogram was constructed to provide more accurate prediction for CSS, and a decision tree was built to identify high-risk subgroup of muscle invasive BCa patients. Overall, the gene signature could be a useful tool to predict CSS and help to identify high-risk subgroup of BCa patients, which may benefit from intensified adjuvant therapy. MDPI 2020-05-02 /pmc/articles/PMC7281226/ /pubmed/32370292 http://dx.doi.org/10.3390/cancers12051146 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Shi, Run
Bao, Xuanwen
Rogowski, Paul
Schäfer, Christian
Schmidt-Hegemann, Nina-Sophie
Unger, Kristian
Lu, Shun
Sun, Jing
Buchner, Alexander
Stief, Christian
Belka, Claus
Li, Minglun
Establishment and Validation of an Individualized Cell Cycle Process-Related Gene Signature to Predict Cancer-Specific Survival in Patients with Bladder Cancer
title Establishment and Validation of an Individualized Cell Cycle Process-Related Gene Signature to Predict Cancer-Specific Survival in Patients with Bladder Cancer
title_full Establishment and Validation of an Individualized Cell Cycle Process-Related Gene Signature to Predict Cancer-Specific Survival in Patients with Bladder Cancer
title_fullStr Establishment and Validation of an Individualized Cell Cycle Process-Related Gene Signature to Predict Cancer-Specific Survival in Patients with Bladder Cancer
title_full_unstemmed Establishment and Validation of an Individualized Cell Cycle Process-Related Gene Signature to Predict Cancer-Specific Survival in Patients with Bladder Cancer
title_short Establishment and Validation of an Individualized Cell Cycle Process-Related Gene Signature to Predict Cancer-Specific Survival in Patients with Bladder Cancer
title_sort establishment and validation of an individualized cell cycle process-related gene signature to predict cancer-specific survival in patients with bladder cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281226/
https://www.ncbi.nlm.nih.gov/pubmed/32370292
http://dx.doi.org/10.3390/cancers12051146
work_keys_str_mv AT shirun establishmentandvalidationofanindividualizedcellcycleprocessrelatedgenesignaturetopredictcancerspecificsurvivalinpatientswithbladdercancer
AT baoxuanwen establishmentandvalidationofanindividualizedcellcycleprocessrelatedgenesignaturetopredictcancerspecificsurvivalinpatientswithbladdercancer
AT rogowskipaul establishmentandvalidationofanindividualizedcellcycleprocessrelatedgenesignaturetopredictcancerspecificsurvivalinpatientswithbladdercancer
AT schaferchristian establishmentandvalidationofanindividualizedcellcycleprocessrelatedgenesignaturetopredictcancerspecificsurvivalinpatientswithbladdercancer
AT schmidthegemannninasophie establishmentandvalidationofanindividualizedcellcycleprocessrelatedgenesignaturetopredictcancerspecificsurvivalinpatientswithbladdercancer
AT ungerkristian establishmentandvalidationofanindividualizedcellcycleprocessrelatedgenesignaturetopredictcancerspecificsurvivalinpatientswithbladdercancer
AT lushun establishmentandvalidationofanindividualizedcellcycleprocessrelatedgenesignaturetopredictcancerspecificsurvivalinpatientswithbladdercancer
AT sunjing establishmentandvalidationofanindividualizedcellcycleprocessrelatedgenesignaturetopredictcancerspecificsurvivalinpatientswithbladdercancer
AT buchneralexander establishmentandvalidationofanindividualizedcellcycleprocessrelatedgenesignaturetopredictcancerspecificsurvivalinpatientswithbladdercancer
AT stiefchristian establishmentandvalidationofanindividualizedcellcycleprocessrelatedgenesignaturetopredictcancerspecificsurvivalinpatientswithbladdercancer
AT belkaclaus establishmentandvalidationofanindividualizedcellcycleprocessrelatedgenesignaturetopredictcancerspecificsurvivalinpatientswithbladdercancer
AT liminglun establishmentandvalidationofanindividualizedcellcycleprocessrelatedgenesignaturetopredictcancerspecificsurvivalinpatientswithbladdercancer